PolarityBio Wins Award for SkinTE Wound Healing Study
Results from the Phase 3 COVER DFUS II trial show SkinTE met its primary endpoint for wound closure in Las Vegas.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Should the government expedite the approval process for new medical treatments like regenerative therapies?
PolarityBio received the Highest Scoring Abstract Award at the Symposium on Advanced Wound Care after presenting positive results from its Phase 3 trial. The study demonstrated that SkinTE achieved complete wound closure within 12 weeks.
Why it matters
The successful trial results provide clinical validation for SkinTE, which is currently undergoing FDA Priority Review to address severe wound care needs. This data supports the potential for a new treatment option for patients facing complex wound healing challenges.
The study met its primary efficacy endpoint of complete wound closure within 12 weeks. Participants were required to have wounds that did not decrease by more than 30% during a two-week run-in period before randomization.
The players
PolarityBio
This biotechnology company is based in Salt Lake City and specializes in developing regenerative medicine therapies.
Robert S. Kirsner
He served as the study chair for the COVER DFUS II trial and presented the findings at the symposium.
The details
The Phase 3 COVER DFUS II trial randomized 120 participants to receive either SkinTE combined with the standard of care or the standard of care alone. SkinTE has already secured Regenerative Medicine Advanced Therapy and Breakthrough Therapy designations from the FDA.
Timeline
September 2026: The FDA granted Priority Review to the SkinTE Biologics License Application.
October 15-18, 2026: The Symposium on Advanced Wound Care took place in Las Vegas.
October 17, 2026: PolarityBio received the Highest Scoring Abstract Award.
March 16, 2027: The FDA target action date for the SkinTE Biologics License Application.
The Big Picture
The SkinTE study follows the development pathway established by the FDA Regenerative Medicine Advanced Therapy designation to expedite novel treatments. This approach marks a shift in how biotech firms engage with regulatory bodies to bring advanced wound care products to market.
The potential approval of SkinTE could provide a new therapeutic option for patients struggling with chronic wounds that fail to respond to standard treatments. Patients may soon see this technology integrated into wound care clinical routines following the March 2027 regulatory deadline.
The takeaway
These trial results demonstrate the efficacy of regenerative therapies in addressing complex wound healing. Continued monitoring of the FDA review process will determine when this treatment becomes available to the broader medical community.
What happens next
The FDA is scheduled to reach a decision on the SkinTE Biologics License Application by the PDUFA target action date of March 16, 2027.
Further reading
For more information on the latest developments in medical innovation, visit the Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Should the government expedite the approval process for new medical treatments like regenerative therapies?
